Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Combination therapy with idelalisib better prevents disease progression in relapsed or treatment-resistant chronic lymphocytic leukaemia than current regimen

Share :

ASH 2015

5 - 7 Dec 2015
Published: 6 Dec 2015
Views: 2033
Rating:
Save
Dr Andrew D. Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Zelenetz presents, at a press conference at ASH 2015, results of a phase III randomised double-blind placebo-controlled study.

Idelalisib plus bendamustine and rituximab is superior to rituximab alone in patients with relapsed/refractory chronic lymphocytic leukaemia.

Read the news story and watch the video interview for more information.

Related Videos

Multiple myeloma in a resource constrained setting
Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda
Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )
22 Feb 2024
Relapsed Refractory Multiple Myeloma
Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India
Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )
5 Dec 2023
OncoAlert Round Up for August 25th - 31st, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
4 Sep 2023
Latest in immunological technologies that can treat, control, and prevent cancer
Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute
Latest in immunological technologies that can treat, control, and prevent cancer ( Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute )
16 Aug 2023
Atezolizumab, obinutuzumab and venetoclax combination is active and leads to...
Prof Anna Maria Frustaci - Niguarda Ca’ Granda Hospital, Milan, Italy
Atezolizumab, obinutuzumab and venetoclax combination is active and leads to durable remissions in previously untreated DLBCL-RS ( Prof Anna Maria Frustaci - Niguarda Ca’ Granda Hospital, Milan, Italy )
16 Jun 2023
Chemotherapy-free combination of ponatinib and blinatumomab results in high...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Chemotherapy-free combination of ponatinib and blinatumomab results in high rates of CMR and NGS MRD negativity in Ph positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
16 Jun 2023
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...
Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )
15 Jun 2023
Belamaf monotherapy induced rapid responses without unexpected toxicity in...
Dr Efstathios Kastritis - National and Kapodistrian University of Athens...
Belamaf monotherapy induced rapid responses without unexpected toxicity in relapsed or refractory light chain amyloidosis ( Dr Efstathios Kastritis - National and Kapodistrian University of Athens, Athens, Greece )
15 Jun 2023
The current status of multiple myeloma diagnosis and treatment
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )
24 May 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation